IVD China last week: Siemens and Rejoin Medical, Agilent and BioRay Pharmaceutical, MGI and JCBio, Berry Genomics and Tencent Cloud

Siemens Partners with Rejoin Medical to Build a Digital Future for Sports Medicine Medical Devices

Siemens Industrial Software (Shanghai) Co., Ltd. and Rejoin Medical recently officially signed a strategic cooperation agreement in Hangzhou. Based on Rejoin Medical’s leading technologies in sports medicine and minimally invasive orthopedic devices, combined with Siemens Industrial Software’s globally leading digital enterprise solutions, the two parties will jointly promote the intelligent upgrade and digital transformation of the orthopedic medical device industry.

Agilent and BioRay Pharmaceutical Launch Strategic Collaboration

Agilent Technologies Inc. and Zhejiang BioRay Pharmaceutical Co., Ltd. recently signed a strategic cooperation agreement to jointly establish an "Innovative Drug Pharmaceutical Research and Quality Control Joint Laboratory." Leveraging this joint laboratory, both parties will fully utilize their respective strengths, adopting an international perspective and globally leading analytical technologies and methodologies to jointly empower the development and application of new concepts and methods in drug analysis and quality control. They will collaborate on developing workflows and application solutions for areas such as analytical characterization of innovative drugs, impurity research, process control, as well as activity analysis and efficacy evaluation.

JCBio and MGI Establish South Korea’s First DCS Lab to Accelerate Multi-Omics Innovation

JCBio, a leading biotechnology company in South Korea, recently signed a Memorandum of Understanding (MoU) with MGI Tech to jointly launch South Korea’s first DCS Lab for cutting-edge omics research. By integrating JCBio’s local innovation experience with MGI’s innovative sequencing technology platforms, the collaboration will accelerate innovation in multi-omics research in South Korea and promote the in-depth application and translation of gene sequencing technologies in key areas such as precision medicine, clinical diagnostics, and AI data analysis.

Berry Genomics Joins Hands with Tencent Cloud to Embark on a New AI-Driven Journey in Life and Health

Beijing Berry and Kang Biotechnology Co., Ltd., a wholly-owned subsidiary of Chengdu Berry and Kang Gene Technology Co., Ltd., has officially signed a Strategic Cooperation Agreement with Tencent Cloud Computing (Beijing) Co., Ltd., a giant in the cloud computing sector. The two parties have decided to forge a deep collaboration to jointly explore the limitless possibilities of artificial intelligence (AI) in the life and health field. This partnership aims to expand the depth and breadth of cooperation, enhance mutual target benefits, and embark on a transformative journey integrating life health with cutting-edge technology.